Nivolumab Plus Ipilimumab Versus EXTREME Regimen as First-Line Treatment for Recurrent/Metastatic Squamous Cell Carcinoma of the Head and Neck: The Final Results of CheckMate 651

CheckMate 651 (ClinicalTrials.gov identifier: NCT02741570) evaluated first-line nivolumab plus ipilimumab versus EXTREME (cetuximab plus cisplatin/carboplatin plus fluorouracil ≤ six cycles, then cetuximab maintenance) in recurrent/metastatic squamous cell carcinoma of the head and neck (R/M SCCHN)....

Descripción completa

Detalles Bibliográficos
Autores principales: Haddad, Robert I., Harrington, Kevin, Tahara, Makoto, Ferris, Robert L., Gillison, Maura, Fayette, Jerome, Daste, Amaury, Koralewski, Piotr, Zurawski, Bogdan, Taberna, Miren, Saba, Nabil F., Mak, Milena, Kawecki, Andrzej, Girotto, Gustavo, Alvarez Avitia, Miguel Angel, Even, Caroline, Toledo, Joaquin Gabriel Reinoso, Guminski, Alexander, Müller-Richter, Urs, Kiyota, Naomi, Roberts, Mustimbo, Khan, Tariq Aziz, Miller-Moslin, Karen, Wei, Li, Argiris, Athanassios
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Wolters Kluwer Health 2023
Materias:
ORIGINAL REPORTS
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10115555/
https://www.ncbi.nlm.nih.gov/pubmed/36473143
http://dx.doi.org/10.1200/JCO.22.00332

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10115555/
https://www.ncbi.nlm.nih.gov/pubmed/36473143
http://dx.doi.org/10.1200/JCO.22.00332

Ejemplares similares